On February 24, 2026, XTL Biopharmaceuticals Ltd. held a meeting where shareholders approved an increase in authorized share capital by 1.45 billion shares and re-elected Iris Shapira Yalon as an external director. Additionally, they authorized a private placement of up to $2 million contingent on a related transaction.